What is VirtualScopics Earnings Yield (Joel Greenblatt) %?
VirtualScopics's Enterprise Value for the quarter that ended in Dec. 2015 was $7.34 Mil.
VirtualScopics's EBIT for the trailing twelve months (TTM) ended in Dec. 2015 was $-1.00 Mil. VirtualScopics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2015 was -13.57%.
The historical rank and industry rank for VirtualScopics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
VSCP's Earnings Yield (Joel Greenblatt) % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.205 * Ranked among companies with meaningful Earnings Yield (Joel Greenblatt) % only.
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. VirtualScopics's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2015 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
VirtualScopics Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for VirtualScopics's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of VirtualScopics's Earnings Yield (Joel Greenblatt) %
For the Medical Devices subindustry, VirtualScopics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VirtualScopics's Earnings Yield (Joel Greenblatt) % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, VirtualScopics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where VirtualScopics's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
VirtualScopicss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2015 is calculated as
VirtualScopics's EBIT for the trailing twelve months (TTM) ended in Dec. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.00 Mil.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
VirtualScopics Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of VirtualScopics's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
VirtualScopics (VirtualScopics) Business Description
VirtualScopics Inc. is a provider of quantitative imaging for clinical trials serving the pharmaceutical, biotechnology and medical device industries. The Company has developed a software platform for analysis and modeling of both structural and functional medical images. This platform provides information about the biological activity of drugs and devices in clinical trial patients. VirtualScopics is an imaging core lab providing central reads and quantitative imaging solutions for drug and medical device clinical trials for the areas of oncology, rheumatoid arthritis, osteoarthritis, neurology, and cardiovascular studies utilizing MRI, PET, CT, Ultrasound, and X-ray imaging modalities. The Company's image-based measurement and visualization tools enable automated and reproducible measurement of minute changes that occur in anatomic structures in musculoskeletal, oncological, cardiological and neurological diseases. The Company's image analysis provides a degree of accuracy and reproducibility that cannot be duplicated by manual techniques. The Company's quantitative imaging replaces subjective evaluation. It has developed a suite of patented semi-automated tools for the identification and measurement of carotid plaques. Evaluating diseases such as multiple sclerosis (MS), epilepsy, and Alzheimer's requires the identification and measurement of neurological structures and lesions. The Company's competition is largely comprised of a limited number of university research centers that are working on developing the next generation of image analysis tools. The Company's main customers are Novartis, Merck Serono and Amgen. The Company's main competitors are clinical research organizations (CROs) providing clinical trial services to pharmaceutical companies. Healthcare in the United States is heavily regulated by the federal government, and by state and local governments.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VSCP has been successfully added to your 